⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2025

Supplementary Figure 3 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer

Eric S. Christenson Won Jin Ho Daniel Shu Jennifer N. Durham Madelena Brancati Heather Davis Bruning Susan Petrie Hao Wang Jiayun Lu Katherine M. Bever Daniel A. Laheru Ana De Jesus‐Acosta Ilene Browner Ross C. Donehower Michael J. Pishvaian Nilofer S. Azad Qingfeng Zhu Alens Valentin Jayalaxmi Suresh Babu Alexei Hernandez George Apostol Yiyang Gao Nicolás J. Llosa Franck Housseau Drew M. Pardoll Elizabeth M. Jaffee Robert A. Anders Dung T. Le

View Full Paper

Ask AI

Bookmark

Share

Key Points

Nivolumab and relatlimab are being assessed for efficacy in treating unresectable colorectal cancer.
CyTOF analysis provides insights on the immune composition of circulating PBMCs in patients.
The study focuses on mismatch repair-proficient colorectal cancer, a challenging cancer type.
Findings may guide future treatments for patients who have limited options available.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

CyTOF analysis reveals immune profiles in patients with unresectable colorectal cancer, suggesting potential treatment pathways.

Abstract

Supplementary Figure 3. CyTOF analysis of circulating PBMCs.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Christenson et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d0215 https://doi.org/10.1158/1078-0432.29760379

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 4 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer2025
2Supplementary Figure 1 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer2025
3Supplementary Figure 2 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer2025
4Supplementary Figure 6 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer2025
5Supplementary Figure 5 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer2025